Advertisement
U.S. markets closed

Leap Therapeutics, Inc. (LPTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.2400+0.1250 (+4.01%)
At close: 04:00PM EDT
3.2300 -0.01 (-0.31%)
After hours: 07:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close3.1150
Open3.1500
Bid3.2000 x 100
Ask3.3600 x 100
Day's Range3.0700 - 3.5000
52 Week Range1.2350 - 10.2000
Volume555,834
Avg. Volume329,474
Market Cap82.955M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-3.9800
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LPTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Leap Therapeutics, Inc.
    Analyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • PR Newswire

    Leap Therapeutics Announces $40 Million Private Placement

    Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise

  • Zacks

    Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks

    Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • PR Newswire

    Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023.